The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesIP: Use at 2-5µg/mg of lysate.
Is unsuitable for WB.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionRequired for innate immune defense against viruses. Acts downstream of DDX58 and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFN-beta and RANTES (CCL5). May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis.
Tissue specificityPresent in T-cells, monocytes, epithelial cells and hepatocytes (at protein level). Ubiquitously expressed, with highest levels in heart, skeletal muscle, liver, placenta and peripheral blood leukocytes.
Sequence similaritiesContains 1 CARD domain.
DomainBoth CARD and transmembrane domains are essential for antiviral function. The CARD domain is responsible for interaction with DDX58 and IFIH1.
Post-translational modificationsUbiquitinated; undergoes 'Lys-48'-linked polyubiquitination catalyzed by ITCH; ITCH-dependent polyubiquitination is mediated by the interaction with PCBP2 and leads to MAVS proteasomal degradation.